Longeveron's Alzheimer's Candidate Meets Safety Goal In Mid-Stage Study
Portfolio Pulse from Vandana Singh
Longeveron Inc announced positive results from the Phase 2a trial of its investigational product Lomecel-B for mild Alzheimer's disease. The primary endpoint of safety was met, with no significant safety issues raised. Statistically significant improvement was observed in Composite Alzheimer's Disease Score (CADS) and slowing of disease progression. However, LGVN shares are down 4.41% at $2.40 on the last check Thursday.
October 05, 2023 | 1:33 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Despite positive trial results for its Alzheimer's drug, Longeveron's stock price fell by 4.41%.
The positive trial results for Longeveron's Alzheimer's drug would typically be expected to boost the company's stock price. However, the stock price fell by 4.41%, indicating that other factors may be influencing investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100